Biosimilar competition can lead to lower prices for biologic medicines and can prompt originator manufacturers to reduce list prices or offer larger rebates, while the magnitude of patient savings depends on insurance coverage decisions and whether a biosimilar is placed on a pharmacy benefit manager's formulary.
high
economic
Typical market and insurance mechanisms affecting patient-level savings from biosimilars.